File HF5147 ("Minnesota modifies tax code, targets pharma marketing") is before the Minnesota Legislature and has not been decided. Latest step (May 14, 2026): Introduction and first reading, referred to.
Minnesota file HF5147, before the Minnesota Legislature. Still to be decided as of 2026-05-14.
Tax liability changes for Minnesota businesses and earners Income and corporate franchise tax rates or brackets shift, but the specific changes and affected income thresholds are not yet clear from the bill's early stage and require review of detailed legislative language.
Pharmaceutical companies face new marketing expense disclosure rules Drug manufacturers operating in Minnesota may be required to separately account for and report marketing expenses, potentially affecting how costs are deducted or taxed and signaling legislative intent to scrutinize pharma pricing practices.
Bill scope and implementation timeline remain unclear The bill is in early stages (first reading); the specific tax provisions being modified, their effective dates, and which taxpayers benefit or bear new burdens cannot be assessed until committee review and floor debate clarify the legislative intent.
Income and corporate franchise tax provisions modified, and addition for pharmaceutical marketing expenses required.
Read the official record for HF5147
See everything up for a vote · This week in Minnesota · See what we have filed with the clerk